Search Results - "TIMAR, Jozsef"

Molecular epidemiology and diagnostics of KRAS mutations in human cancer by Timar, Jozsef, Kashofer, Karl

“…RAS mutation is the most frequent oncogenic alteration in human cancers. KRAS is the most frequently mutated followed by NRAS. The emblematic KRAS mutant…”
Get full text

Guest editorial/preface by Tímár, József

Get full text

The clinical relevance of KRAS gene mutation in non-small-cell lung cancer by Tímár, József

“…PURPOSE OF REVIEWThere are conflicting data on the potential prognostic and predictive role of mutant KRAS in non-small-cell lung cancer (NSCLC). RECENT…”
Get full text

On-Target Side Effects of Targeted Therapeutics of Cancer by Tímár, József, Uhlyarik, Andrea

“…The concept of precision medicine is based on the identification of hallmarks of cancer to exploit them as drug targets. The basic idea was that in this way…”
Get full text

KRASG12C mutant lung adenocarcinoma: unique biology, novel therapies and new challenges by Moldvay, Judit, Tímár, József

“…KRAS mutant lung cancer is the most prevalent molecular subclass of adenocarcinoma (LUAD), which is a heterogenous group depending on the mutation-type which…”
Get full text

Immunologic and immunogenomic aspects of tumor progression by Ladányi, Andrea, Tímár, József

“…Tumor progression to metastatic disease is characterized by continuous genetic alterations due to instability of the genome. Immune sensitivity was found to be…”
Get full text

Hypoxia Signaling in Cancer: From Basics to Clinical Practice by Sebestyén, Anna, Kopper, László, Dankó, Titanilla, Tímár, József

“…Cancer hypoxia, recognized as one of the most important hallmarks of cancer, affects gene expression, metabolism and ultimately tumor biology-related…”
Get full text

Genetic evolution during tumor progression: from basic research to clinical practice by Tímár, József

Get full text

Prognostic impact of B-cell density in cutaneous melanoma by Ladányi, Andrea, Kiss, Judit, Mohos, Anita, Somlai, Beáta, Liszkay, Gabriella, Gilde, Katalin, Fejős, Zsuzsanna, Gaudi, István, Dobos, Judit, Tímár, József

“…Studies on the prognostic importance of tumor-infiltrating lymphocytes have mainly focused on T cells, while little is known about the role of…”
Get full text

Metastatic Progression of Human Melanoma by Tímár, József, Ladányi, Andrea

“…This Topical Collection, comprising 13 papers (10 original articles and 3 reviews), addresses various aspects of the field of melanoma progression: genomic and…”
Get full text

RecurrenceOnline: an online analysis tool to determine breast cancer recurrence and hormone receptor status using microarray data by Győrffy, Balázs, Benke, Zsombor, Lánczky, András, Balázs, Bálint, Szállási, Zoltán, Timár, József, Schäfer, Reinhold

“…In the last decades, several gene expression-based predictors of clinical behavior were developed for breast cancer. A common feature of these is the use of…”
Get full text

Editorial: Pathology and Oncology Research: addressing publication ethics issues by Tímár, József, Ladányi, Andrea, Sebestyén, Anna, Kopper, László

Get full text

Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development by Ranđelović, Ivan, Nyíri, Kinga, Koppány, Gergely, Baranyi, Marcell, Tóvári, József, Kigyós, Attila, Tímár, József, Vértessy, Beáta G, Grolmusz, Vince

“…Mutated genes may lead to cancer development in numerous tissues. While more than 600 cancer-causing genes are known today, some of the most widespread…”
Get full text

Expression of calcium pumps is differentially regulated by histone deacetylase inhibitors and estrogen receptor alpha in breast cancer cells by Varga, Karolina, Hollósi, Anna, Pászty, Katalin, Hegedűs, Luca, Szakács, Gergely, Tímár, József, Papp, Béla, Enyedi, Ágnes, Padányi, Rita

“…Remodeling of Ca signaling is an important step in cancer progression, and altered expression of members of the Ca signaling toolkit including the plasma…”
Get full text

Comparison of standard mismatch repair deficiency and microsatellite instability tests in a large cancer series by Nádorvári, Maja L, Kenessey, István, Kiss, András, Barbai, Tamás, Kulka, Janina, Rásó, Erzsébet, Tímár, József

“…The tumor-agnostic indication of immune checkpoint inhibitors to treat cancers with mismatch repair deficiency (dMMR)/microsatellite instability (MSI)…”
Get full text

Scientific integrity in the era of predatory journals: Insights from an editors in chief symposium by Benyó, Zoltan, Clementi, Emilio, Cremers, Serge, Dávid, Beáta, Guzik, Tomasz, Heusch, Gerd, Jarvis, Michael, Orhan, Kaan, Seifert, Roland, Tímár, József, Ungvari, Zoltan, Ferdinandy, Péter

Get full text

Microsatellite instability and mismatch repair protein deficiency: equal predictive markers? by Nádorvári, Maja L, Lotz, Gábor, Kulka, Janina, Kiss, András, Tímár, József

“…Current clinical guidelines recommend mismatch repair (MMR) protein immunohistochemistry (IHC) or molecular microsatellite instability (MSI) tests as…”
Get full text

The role of lipid signaling in the progression of malignant melanoma by Tímár, József, Hegedüs, B., Rásó, E.

“…In the past decades, a vast amount of data accumulated on the role of lipid signaling pathways in the progression of malignant melanoma, the most…”
Get full text

Long-Term Vemurafenib Exposure Induced Alterations of Cell Phenotypes in Melanoma: Increased Cell Migration and Its Association with EGFR Expression by Molnár, Eszter, Garay, Tamás, Donia, Marco, Baranyi, Marcell, Rittler, Dominika, Berger, Walter, Tímár, József, Grusch, Michael, Hegedűs, Balázs

“…Acquired resistance during BRAF inhibitor therapy remains a major challenge for melanoma treatment. Accordingly, we evaluated the phenotypical and molecular…”
Get full text

Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients by Rojkó, Lívia, Reiniger, Lilla, Téglási, Vanda, Fábián, Katalin, Pipek, Orsolya, Vágvölgyi, Attila, Agócs, László, Fillinger, János, Kajdácsi, Zita, Tímár, József, Döme, Balázs, Szállási, Zoltán, Moldvay, Judit

“…Objectives While the predictive value of programmed cell death ligand-1 (PD-L1) protein expression for immune checkpoint inhibitor therapy of lung cancer has…”
Get full text